Blood Markers Show Promise in Tracking Lecanemab's Amyloid Clearance in Alzheimer's Disease

A longitudinal study published in The Lancet Neurology suggests that certain blood proteins could eventually help clinicians assess amyloid clearance and counsel patients receiving lecanemab for early Alzheimer's disease. While these findings require further validation, they offer potential for guiding treatment duration and monitoring.